Li Hui, Xie Lu, Yao Hongdi, Zhang Lexing, Liang Sanhong, Lyu Wen
Department of Gastroenterology, Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Zhejiang Chinese Medical University School, Hangzhou, Zhejiang, People's Republic of China.
Int Med Case Rep J. 2022 Mar 29;15:117-124. doi: 10.2147/IMCRJ.S346159. eCollection 2022.
The incidences of enterovesical and enterocutaneous fistulas are extremely low, and enterovesical and enterocutaneous fistulas are difficult to treat in patients with Crohn's disease.
In this case, the patient had recurrent abdominal pain and diarrhea for more than 2 years, with fecal residue in the urine for 6 days. Pelvic magnetic resonance imaging and colonoscopy showed intestinal infection with a rectal fistula, and the initial diagnosis was severely active Crohn's disease with an enterovesical fistula. The patient had multiple internal fistulas and infections, and strongly refused surgical conditions. The patient was given an intravenous infusion of ustekinumab and somatostatin, with anti-infective treatment, nutritional support and regulation of the intestinal flora. Drainage and debridement of the cutaneous fistula were performed. After comprehensive treatment and management, the patient's condition achieved significant clinical remission.
This patient achieved clinical response and will receive follow-up for another dose of ustekinumab after 12 weeks. The patient developed enterovesical and enterocutaneous fistulas, the incidence of multiple fistulas which are low in patients with CD and are difficult to cure and prone to relapse. Only few patients achieve complete remission. At present, there is no standard and effective treatment for CD with multiple fistulas. Usually, surgery is performed for treatment. Drug therapy, especially with biological agents, should be selected as the first-line pre-operative treatment. Clinicians, especially gastroenterologists, need to improve their knowledge of these conditions and update the treatment consensus guidelines in a timely manner. Clinicians need to take into account the patient's condition and willingness when developing an effective treatment plan.
肠膀胱瘘和肠皮肤瘘的发病率极低,且在克罗恩病患者中难以治疗。
在此病例中,患者反复腹痛、腹泻2年余,伴6天尿中带粪渣。盆腔磁共振成像及结肠镜检查显示肠道感染伴直肠瘘,初步诊断为重度活动性克罗恩病伴肠膀胱瘘。患者存在多处内瘘及感染,强烈拒绝手术治疗。给予患者静脉输注优特克单抗及生长抑素,并进行抗感染治疗、营养支持及调节肠道菌群。对皮肤瘘进行了引流和清创。经过综合治疗及管理,患者病情取得显著临床缓解。
该患者取得了临床反应,12周后将接受另一剂优特克单抗的随访。该患者出现了肠膀胱瘘和肠皮肤瘘,多发瘘在克罗恩病患者中发病率低,难以治愈且易于复发。仅有少数患者能实现完全缓解。目前,对于伴有多发瘘的克罗恩病尚无标准有效的治疗方法。通常采用手术治疗。药物治疗,尤其是生物制剂,应作为术前一线治疗选择。临床医生,尤其是胃肠病学家,需要提高对这些病症的认识,并及时更新治疗共识指南。临床医生在制定有效治疗方案时需要考虑患者的病情及意愿。